Literature DB >> 2016540

Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium.

R W Baird1, M S Bronze, W Kraus, H R Hill, L G Veasey, J B Dale.   

Abstract

Rabbit antisera evoked by purified pepsin-extracted group A streptococcal M proteins were screened for the presence of joint cross-reactive antibodies by indirect immunofluorescence using thin sections of mouse knee joints. Pep M1, M5, and M18 antisera contained antibodies that cross-reacted with chondrocytes, cartilage, and synovium. Immunofluorescence inhibition assays showed that some of the joint cross-reactive epitopes were shared among the three heterologous serotypes of M protein. The pep M5 joint cross-reactive epitopes were localized to three different synthetic peptides of the C-terminal region of pep M5. Immunoblot analyses showed that the M5 joint cross-reactive antibodies recognized two proteins of human synovium and cartilage of molecular mass 56 and 58 kDa. The cross-reactive antibodies binding to the 56-kDa protein were inhibited by purified vimentin in immunoblot inhibition experiments. M protein-specific antibodies from patients with acute rheumatic fever were also shown to cross-react with joint tissue in a pattern similar to the rabbit antisera. Rabbit and human M protein-specific antibodies that were bound to articular cartilage activated significant levels of complement when compared to control serum, suggesting that M protein joint cross-reactive antibodies could potentially be involved in the pathogenesis of ARF and arthritis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016540

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Immunogenicity of a 26-valent group A streptococcal vaccine.

Authors:  Mary C Hu; Michael A Walls; Steven D Stroop; Mark A Reddish; Bernard Beall; James B Dale
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

Review 2.  Th2 mediated regulation in RA and the spondyloarthropathies.

Authors:  J A G van Roon; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 3.  Molecular mimicry--hypothesis or reality?

Authors:  N Tsuchiya; R C Williams
Journal:  West J Med       Date:  1992-08

4.  Anti-Hsp65 antibodies recognize M proteins of group A streptococci.

Authors:  A Quinn; T M Shinnick; M W Cunningham
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

5.  Spa contributes to the virulence of type 18 group A streptococci.

Authors:  D G McLellan; E Y Chiang; H S Courtney; D L Hasty; S C Wei; M C Hu; M A Walls; J J Bloom; J B Dale
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

6.  Immunogenicity of a divalent group A streptococcal vaccine.

Authors:  Yuexia Ding; Qiongqiong Ni; Jinlai Liu; Buyun Yu
Journal:  Rheumatol Int       Date:  2012-08-08       Impact factor: 2.631

7.  Antibodies against proteins of streptococcal hyaluronate synthase bind to human fibroblasts and are present in patients with rheumatic fever.

Authors:  S Prehm; C Herrington; V Nickel; W Völker; N I Briko; E I Blinnikova; A Schmiedel; P Prehm
Journal:  J Anat       Date:  1995-10       Impact factor: 2.610

Review 8.  Beta haemolytic streptococci and reactive arthritis in adults.

Authors:  C Deighton
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

9.  Epidemiology of Invasive Group A Streptococcal Disease in Alaska, 2001 to 2013.

Authors:  Karen Rudolph; Michael G Bruce; Dana Bruden; Tammy Zulz; Alisa Reasonover; Debby Hurlburt; Thomas Hennessy
Journal:  J Clin Microbiol       Date:  2015-11-11       Impact factor: 5.948

10.  Inhibition of human peripheral blood mononuclear cell proliferation by Streptococcus pyogenes cell extract is associated with arginine deiminase activity.

Authors:  B A Degnan; J M Palmer; T Robson; C E Jones; M Fischer; M Glanville; G D Mellor; A G Diamond; M A Kehoe; J A Goodacre
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.